SCHEMBL34461777

SCHEMBL34461777

C=CC(=O)Nc1ccccc1-n1ccc2c1c(=O)n1c(C)nnc1n2CC(=O)Nc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.39
▸ MAPT P10636 4/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ HTT P42858 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ POLB P06746 1/20 0.34
▸ TP53 P04637 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ FGFR4 P22455 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34461737 0.89 TRPA1 (0.41) MAPTRXFP1TP53KDM4ETSHR
SCHEMBL34461730 0.85 NPC1 (0.41) MAPTKMT2AMEN1RXFP1POLB
SCHEMBL34461717 0.81 TRPA1 (0.42) MAPTTP53KDM4E
SCHEMBL34461769 0.81 MAP3K7 (0.31) —
SCHEMBL34461721 0.80 TRPA1 (0.40) MAPTRXFP1TP53KDM4ETSHR
SCHEMBL34461766 0.78 KDM4E (0.39) MAPTKMT2AMEN1ALDH1A1HTT
SCHEMBL34461758 0.77 TRPA1 (0.45) MAPTKMT2ARXFP1TP53KDM4E
SCHEMBL34461716 0.76 TRPA1 (0.40) MAPTRXFP1TP53KDM4E
SCHEMBL34461722 0.75 TRPA1 (0.43) MAPTKMT2AMEN1ALDH1A1HTT
SCHEMBL34461761 0.72 TRPA1 (0.41) MAPTRXFP1POLBKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 — — US claimed
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS WRN, POLR1A, REV1 ACHE 4427/4885MAPT 4869/4885KMT2A 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback